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Multiple HIV-1/M + HIV-1/O dual 
infections and new HIV-1/MO inter-group 
recombinant forms detected in Cameroon
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Elodie Alessandri‑Gradt1,2, François Simon5, Dominique Rousset3,6 and Jean‑Christophe Plantier1,2*
Abstract 
Background: Due to the prevalence of HIV‑1 group M and the endemicity of HIV‑1 group O infections in Cameroon, 
patients may be infected with both viruses and/or with HIV‑1/MO recombinant forms. Such atypical infections may be 
deleterious in terms of diagnosis and therapeutic management due to the high divergence of HIV‑1/O. The aim of this 
study was to identify prospectively such atypical infections in Cameroon.
Results: Based on serological screening by env‑V3 serotyping and a molecular strategy using group‑specific (RT)‑
PCRs, we identified 10 Cameroonian patients harboring three different profiles of infection: (1) 4 HIV‑1/M + O dual 
infections without evidence of recombinant; (2) 5 recombinants associated with one or both parental strains; and (3) 1 
new recombinant form without parental strains.
Conclusions: This work highlights the dynamic co‑evolution of these two HIV groups in Cameroon that could lead 
to the emergence of a circulating recombinant form MO, and the need for accurate identification of such atypical 
infections for precise diagnosis, virological monitoring and therapeutic management with adapted tools.
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Background
The Human Immunodeficiency Virus type 1 (HIV-1) 
displays an extraordinary genetic diversity, divided into 
four groups (M to P) [1–4] due to simian origins, errors 
in reverse transcription, and a high recombinogenic 
potential. This latter accentuates diversity and evolution 
through the dynamic generation of multiple recombinant 
forms. At least 79 circulating recombinant forms (CRFs) 
and numerous unique recombinant forms (URFs) are 
now described for HIV-1 group M (HIV-1/M), account-
ing for almost 20% of all HIV infections (http://www.
hiv.lanl.gov/, accessed in October 2016) [5]. Recombina-
tion is not restricted to HIV-1/M, since one intra-HIV-1 
group O (HIV-1/O) recombinant as well as one HIV-2 
CRF have also been reported [6, 7]. CRFs/URFs emerge 
in epidemiological conditions where two (or more) differ-
ent strains predominate. The resulting dual (or multiple) 
infections [8] can generate recombinants that potentially 
spread in the population.
In Cameroon, besides the pandemic group M, all 
HIV-1 divergent groups described to date (N, O and P) 
are in circulation, with HIV-1/O representing about 1% 
of all HIV infections [9]. Despite the genetic distance 
between groups M and O, inter-group recombination is 
possible; three HIV-1/MO recombinant forms were thus 
reported in 1999 and 2004 in Cameroonian patients, 
also infected by the parental HIV-1/O and/or HIV-
1/M strains [10–12]. The transmission potential of such 
recombinant forms was demonstrated by the description 
in 2010 of a fourth recombinant detected in the absence 
of parental strains in a Cameroonian patient living in 
France [13], and more recently by the transmission of a 
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unique HIV-1/MO recombinant form in a Cameroonian 
couple [14].
These limited observations do not enable assessment 
of either the prevalence of these dual infections or the 
dynamic evolution and impact of their associated recom-
binant forms. But, it is known that presence of HIV-1/O 
in some part of the genome and/or in dual infections can 
have serious consequences at the individual level, raising 
future public health concerns. Indeed, HIV-1/O strains 
are characterized by high genetic diversity compared to 
HIV-1/M [6, 15] implying: (1) antigenic consequences 
that may result in false negative serological testing [16–
18]; (2) genetic consequences that may lead to misquan-
tification of the RNA viral load using group-M specific 
kits [19–21], and the need for specific assays for anti-
retroviral (ARV) resistance genotyping [9, 22]; and (3) 
therapeutic consequences, with a natural resistance to 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNR-
TIs) and poor predictive value of the genotypic resistance 
interpretation algorithms used for HIV-1/M [22–25].
Because HIV-1/O prevalence in Cameroon appears to 
have remained stable for many decades while HIV-1/M 
has expanded rapidly [26, 27], the co-circulation of these 
two different groups in the Cameroonian population may 
facilitate HIV-1/M + O dual infections and the genesis of 
HIV-1/MO recombinants.
The aim of this work was to identify prospectively 
such atypical infections in Cameroon, with an effec-
tive strategy combining a serological screening based on 
V3-serotyping and a molecular characterization using 
group-specific (RT)-PCRs.
Methods
Characteristics of samples
Between March 2006 and July 2009, 6796 serum samples 
were prospectively diagnosed HIV positive using a diag-
nosis strategy previously described as part of the routine 
laboratory activities of the Centre Pasteur du Cameroun 
(CPC) [28]. In the same period, 15,000 HIV plasma sam-
ples were received for viral load (VL) monitoring of pre-
viously diagnosed HIV positive patients. Buffy coats were 
also available for some patients.
Serotyping screening of potential HIV‑1/M + O dual 
infections
To discriminate between HIV-1/M or HIV-1/O mono-
infections and HIV-1/M +  O dual infections, all serum 
and plasma samples were screened with a serotyping 
ELISA test using a previously described method based on 
specific antigenic peptides of the env -V3 loop from both 
HIV-1/O (V3-O) and HIV-1/M (V3-M) [28].
Molecular confirmation of HIV‑1/M + O dual infections
All samples considered as dual seroreactive were fur-
ther investigated using group-O and group-M specific 
PCRs or RT-PCRs, followed by sequencing. Due to the 
recombinant patterns previously published, four regions 
were targeted: the Protease (PR), Reverse Transcriptase 
(RT), and Integrase (IN) in pol; and the gp41 in env. The 
position of the different primers on the HIV-1 genome 
is summarized in Fig.  1. Primer sequences, amplified 
fragment lengths, and PCR conditions were previously 
detailed in former publications [6, 9, 22, 29–31].
Molecular detection of HIV‑1 M/O recombinant in vpr
As characterization of the partial or complete genomes 
of the three recombinant forms (described before the 
start of this work), revealed a breakpoint in vpr for two 
of them [10, 11], we hypothesized that this gene could be 
considered as a hotspot and it was included in our molec-
ular strategy. Putative recombinants with a breakpoint 
in the Vpr region (designated as vpr recombinants) were 
investigated with a nested PCR protocol [10] that cov-
ered the region between the middle of vif to the middle 
of vpu (Fig. 1). Identification of vpr recombinants in both 
[M–O] and [O–M] patterns were made possible by the 
use of heterologous primers: MVIF/OVPU and OVIF/
MVPU respectively. Presence of parental HIV-1/M and 
HIV-1/O strains was revealed by using the homologous 
primers MVIF/MVPU and OVIF/OVPU.
Near full‑length genome sequencing
Near full-length genome characterization was obtained 
from RNA extracted from two samples by the amplifi-
cation of overlapping fragments using group-specific 
RT-PCR, followed by nested PCR and sequencing as pre-
viously described [14].
Phylogenetic and recombination analyses
Group specific PCR fragments and vpr fragments were 
sequenced and aligned along with a set of different HIV-
1/M and HIV-1/O reference sequences from the LANL 
database using MEGA 5.05 software [32]. vpr sequences 
from the recombinants described by Peeters et  al. [10], 
Yamaguchi et  al. [12], Vessière et  al. [13] and Ngoupo 
et al. [14] were also included in the alignment (GenBank 
access No AJ239083, AY489738, GQ351296, KM438031 
and KM438032). Genotyping was performed using HIV 
BLAST (http://lanl.hiv.org), Genotyping Retrovirus Tool 
(http://www.ncbi.nlm.nih.gov/retroviruses/) and REGA 
HIV-1 Subtyping Tool (http://dbpartners.stanford.edu/
RegaSubtyping/). For recombination analyses, we per-
formed: Similarity analysis, allowing localization of the 
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recombination points, with SimPlot software [33]; and 
the Recombinant Identification Program (RIP) available 
on-line through the Los Alamos Database [34].
Construction of phylogenetic trees was performed 
using MEGA; genetic distances were calculated with 
the Kimura two-parameter method, and trees were 
obtained by the neighbor-joining method. The reliability 
of the branching order was estimated by 1000 bootstrap 
replicates.
Results
HIV‑1/O mono‑reactivities and HIV‑1/M + O dual 
reactivities
During the 40-month period of the study, 61 of the 6796 
HIV positive sera and 81 of the 15,000 plasma for viral 
load were reactive against at least the V3-O antigen. 
Among these 142 V3-O positive samples, 53 (37.6%) pre-
sented V3-O + V3-M dual seroreactivity.
Molecular confirmation of HIV‑1/M + O dual infections 
and detection of HIV‑1/MO recombinant forms
HIV-1/M  +  O dual infection was defined as the pres-
ence of both HIV-1/O and M genomes in a sample; it was 
explored with group specific PCRs in 39/53 samples with 
dual seroreactivity. Fourteen samples were not tested 
because of a lack of material (plasma/serum or buffy 
coat). Molecular analysis showed that most dual reactivi-
ties with serological tests corresponded to non-specific 
cross-reactivities with V3-M or V3-O antigens. Among 
the 39 dual seroreactivities, 23 (59%) were positive 
only with group-O specific PCR in all of the four genes, 
and sequencing confirmed HIV-1/O fragments. These 
samples were considered as HIV-1/O mono-infections, 
i.e. presence of group O species only. Conversely, 6 (15%) 
were considered as HIV-1/M mono-infections, i.e. pres-
ence of group M species only.
Both HIV-1/M and O genomes were detected in 10 
of the 39 (26%) patients. Molecular profiles and phylo-
genetic analyses are detailed in Table  1 and Fig.  2. vpr 
amplification and sequencing data allowed us to define 
three different profiles of infections:
•  dual infections without evidence of a vpr recombinant
Both HIV-1/M and O genomes were detected in four 
samples (YBF221, YBF280, YBF301, and YBF320). Both 
strains were characterized in the four genes using plasma 
(YBF221, YBF280) or buffy coat (YBF301, YBF320) 
(Table  1). The vpr PCR confirmed the results obtained 
with group specific PCRs, i.e. only the O–O and M–M 
homologous primers yielded an amplification fragment.
•  vpr recombinants associated with one or both parental 
strains
We identified two samples (YBF211 and YBF212) 
for which both HIV-1/M and O strains were detected 
in the four genes. The sequence analysis of vpr frag-
ments obtained with heterologous primers showed a 
recombination point in this gene (Fig.  3). For a third 
sample, YBF205, the results of the group-specific PCRs 
performed on the buffy coat indicated the presence 
of HIV-1/O sequences in all regions, and of HIV-1/M 
sequences only in the PR, IN and gp41 regions. The 
Fig. 1 Position of HIV‑1/O and HIV‑1/M specific primers [cf materials and methods]. In blue, HIV‑1/O target regions, in red, HIV‑1/M. The lengths of 
the PCR fragment are respectively: PRM 507 pb, RTM 805 pb, PRO 452 pb, RTO 883 pb, INM 239 pb, INO 192 pb, MVIF‑MVPU 891 pb, OVIF‑OVPU 816 
pb, MVIF‑OVPU 815 pb, OVIF‑MPVU 895 pb, GPM 656 pb, and GPO 674 pb. The position numbers are relative to HXB2 (GenBank accession number 
K03455)
Page 4 of 11De Oliveira et al. Retrovirology  (2017) 14:1 
Ta
bl
e 
1 
M
ol
ec
ul
ar
 p
ro
fil
es
 o
f t
he
 1
0 
sa
m
pl
es
 p
re
se
nt
in
g 
a 
du
al
 in
fe
ct
io
n 
H
IV
-1
/M
+O
 a
nd
/o
r a
 H
IV
-1
/M
O
 re
co
m
bi
na
nt
 fo
rm
N
T 
no
n 
ty
pa
bl
e,
 N
A 
no
t a
va
ila
bl
e
a  
Ac
co
rd
in
g 
to
 c
la
ss
ifi
ca
tio
n 
de
sc
rib
ed
 b
y 
Le
oz
 &
 a
l P
Lo
S 
Pa
th
og
, 2
01
5 
(1
6)
b  
A
m
pl
ifi
ca
tio
n 
an
d 
se
qu
en
ci
ng
 o
f D
N
A
 fr
om
 b
uff
y 
co
at
Sa
m
pl
es
Sa
m
pl
e 
co
lle
ct
io
n 
da
te
Pr
ot
ea
se
RT
In
te
gr
as
e
En
ve
lo
pe
H
IV
‑1
/O
H
IV
‑1
/M
vp
r
Su
bg
ro
up
a
Su
bt
yp
e
H
IV
‑1
/O
H
IV
‑1
/M
H
IV
‑1
/M
O
H
IV
‑1
/O
M
YB
F2
21
10
/1
9/
20
06
M
 +
 O
M
 +
 O
M
 +
 O
M
 +
 O
H
C
RF
02
+
+
−
−
YB
F2
80
N
A
M
 +
 O
M
 +
 O
M
 +
 O
M
 +
 O
T
C
RF
02
+
+
−
−
YB
F3
01
b
10
/1
6/
20
07
M
 +
 O
M
 +
 O
M
 +
 O
M
 +
 O
H
C
RF
02
+
+
−
−
YB
F3
20
b
N
A
M
 +
 O
M
 +
 O
M
 +
 O
M
 +
 O
H
C
RF
02
+
+
−
−
YB
F2
11
b
05
/0
4/
20
09
M
 +
 O
M
 +
 O
M
 +
 O
M
 +
 O
H
C
RF
02
+
+
−
+
YB
F2
12
b
12
/1
1/
20
06
M
 +
 O
M
 +
 O
M
 +
 O
M
 +
 O
H
C
RF
02
+
+
−
+
YB
F2
05
b
09
/1
3/
20
07
M
 +
 O
O
M
 +
 O
M
 +
 O
H
N
T
+
−
−
+
YB
F2
74
05
/1
4/
20
08
O
O
O
M
 +
 O
H
D
+
−
−
+
YB
F2
98
b
11
/0
6/
20
07
M
M
M
M
 +
 O
H
C
RF
02
−
+
+
−
YB
F2
82
04
/0
7/
20
07
M
M
M
O
H
C
RF
02
−
+
−
−
Page 5 of 11De Oliveira et al. Retrovirology  (2017) 14:1 
heterologous vpr PCR revealed the presence of an HIV-1 
[OM] recombinant. The absence of amplification of HIV-
1/M in two genes prevented us from concluding between 
a dual infection associated with a vpr recombinant or an 
HIV-1/O single infection associated with a recombinant 
with a complex pattern.
For two other patients (YBF274 and YBF298), the results 
of the group specific PCRs or RT-PCRs of the pol and env 
genes were discordant, with only one strain amplified 
in pol (HIV-1/O strain for the YBF274 sample and HIV-
1/M strain for YBF298), and the two populations, M and 
O, in env. These profiles associated with the results of vpr 
Fig. 2 Phylogenetic trees of a the Protease‑RT (899 bp) and b the gp41 (443 pb) regions. Sequences representative of HIV‑1/M and HIV‑1/O were 
downloaded from the Los Alamos database (hptt://www.hiv.lanl.gov). The four HIV‑1/MO recombinants: (1) 97CA.MP645MO [10], (2) 02O.CM.1999.
DSC1320 [12], (3) DO.FR.2008.RBF208 [13], and (4) KM438031 and KM438032 [14] are represented in bold italics. The new sequences obtained here 
are represented in bold. The gp41 HIV‑1/O sequence of YBF298 could not be used for phylogenetic analysis, because of the relatively short length 
of the strain. SIVcpzGAB was used as the outgroup. Phylogenetic analyses were performed using MEGA software [32]: evolutionary distances were 
computed using the Kimura 2‑parameter method; 1000 bootstrap replicates were performed to assess the reliability of the branching order. Boot‑
strap values are shown only when significant (>70)
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amplification indicated a vpr recombinant, associated with 
only one parental virus (Table 1). For YBF274, sequencing 
of the complete genome of the recombinant form, showed 
a mosaic pattern with gag-pol belonging to group O (sub-
group H) and env belonging to group M (subtype D), with 
two breakpoints, in vpr and in LTR (Fig. 4a). For YBF298, 
similarity analyses showed homology with the recombi-
nant form 97CA.MP645 previously described by Peeters 
et  al. [10]. Indeed, an HIV-1/M fragment was detected in 
the four regions as well as a group O fragment in the enve-
lope (Table  1). The sequence alignment and the recombi-
nant [MO] profile in the vpr gene showed a recombination 
breakpoint at the same localization as for 97CA.MP645 
(Figs. 2 and 4). This lead us to conclude to a single HIV-1/M 
infection associated with the presence of an [MO] recom-
binant pattern (Table 1), as for 97CA.MP645. Phylogenetic 
analysis showed a strong link between YBF298 and 97CA.
MP645 in the HIV-1/M pol fragment (Fig. 2).
•  Recombinant form only with breakpoint outside vpr
For the YBF282 sample, group specific PCRs were dis-
cordant in pol and env, suggesting the presence of a [MO] 
recombinant virus (Table 1). However, only the presence 
of an HIV-1/M fragment was detected in the targeted vpr 
gene. These results suggest the existence of a recombi-
nant virus with the breakpoint situated downstream of 
vpr. Sequencing of the complete genome confirmed the 
pattern pol M (subtype CRF02_AG) and env O (subgroup 
H), with two breakpoints, in vpu and at the end of gp41 
(Fig. 4b).
Characterization of the ARV resistance profiles of the 
Protease and Reverse Transcriptase regions of the HIV‑1/O 
and HIV‑1/M fragments
Partial amplification of pol gave us the opportunity to 
analyze the ARV resistance profiles of these new strains 
involved in multiple infections associated or not with 
recombinant viruses. We performed interpretation of 
resistance of the HIV-1/M and HIV-1/O species accord-
ing to v25 of the ANRS algorithm for interpretation of 
resistance (http://www.hivfrenchresistance.org/). The 
HIV-1/M PR sequences harbored mutations confer-
ring resistance or possible resistance to nelfinavir and/
or saquinavir, for three of the samples (YBF301, YBF205, 
and YBF298) (Table 2). On the RT sequences, resistance 
Fig. 3 Similarity plots for vpr sequences of the 5 recombinant forms. Plots were generated by SimPlot software with 200 nucleotide (nt) win‑
dows, 20 nt increments, and the Kimura 2‑parameter method with a transition‑transversion (Ts/Tv) ratio of 2.0. Each of the 5 samples (YBF211 
(a), YBF212 (b), YBF205 (c), YBF298 (d), and YBF274 (e)) was queried against an HIV‑1/M subtype CRF02‑AG (02_AG.IBNG.L39106) or subtype D 
(D.UG.92.92UG001.AJ320484) in red, and an HIV‑1/O (O.BE.87.ANT70.L20587) in blue. YBF298 (d) was also queried against the recombinant form 
97CA.MP645 (grey line) previously described by Peeters et al. [10]
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Window : 350 bp, Step: 20 bp, GapStrip: On, Kimura (2-parameter), T/t: 2,0
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Fig. 4 a Recombination pattern of the full‑length genome of YBF274. Analysis was performed using SimPlot software with 250 nucleotide (nt) win‑
dows, 20 nt increments, and the Kimura 2‑parameter method with a transition‑transversion (Ts/Tv) ratio of 2.0. Sequences representative of a strain 
of HIV‑1/M (D.CD.1983.ELI_patent.A07108 in red) and O (O.CM.98.98CMA104.AY169802 in blue) were used. The genome map was obtained using 
the Recombinant HIV Drawing Tool (http://www.hiv.lanl.gov/content/sequence/DRAW_CRF/recom_mapper.html). b Recombination pattern of the 
full‑length genome of YBF282. Analysis was performed using SimPlot software with 350 nucleotide (nt) windows, 20 nt increments, and the Kimura 
2‑parameter method with a transition‑transversion (Ts/Tv) ratio of 2.0. Sequences representative of a strain of HIV‑1/M (02_AG.NG.IBNG‑patent 
DD409979 in red) and O (O.CM.98.98CMA104.AY169802 in blue) were used. The genome map was obtained using the Recombinant HIV Drawing 
Tool (http://www.hiv.lanl.gov/content/sequence/DRAW_CRF/recom_mapper.html)
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mutations were observed only for YBF212, leading to 
resistance to rilpivirine and possible resistance to etra-
virine. Many more mutations for PR and RT of HIV-1/O 
species were observed, leading to: (1) resistance or pos-
sible resistance to atazanavir, indinavir, lopinavir and 
saquinavir; (2) resistance to all NNRTI classes for 6 of 
8 viruses (YBF221, YBF301, YBF320, YBF211, YBF212, 
YBF274) due to the presence of Y181C residue; and (3) 
resistance to lamivudine/emtricitabine and possible 
resistance to abacavir for two of the samples (YBF221 
and YBF301) due to the presence of M184V residue.
Discussion
The aim of this work was to detect HIV-1/M +  O dual 
infections and inter-group recombinant forms in Cam-
eroon. We designed a sero-molecular strategy based 
Table 2 Resistance profiles of  the 10 samples presenting a dual infection HIV-1/M+O and/or a HIV-1/MO recombinant 
form
a According to the ANRS resistance interpretation’s algorithm v25
b In underline = resistance; italic = possible resistance
Samples Profile Protease RT Resistance associated mutations and resistance interpretationa
HIV‑1/M species HIV‑1/O species
Protease RT Resistance 
profileb
Protease RT Resistance 
profile
YBF221 Dual M + O M + O K20I M36I 
L63P/L L89M
V90I L10V L33I M36I 
M46L/M I62V 
A71V K20C 
L63T L89T
T69S M184V 
A98G V179E 
Y181C L210Y
ATV, IDV, 3TC/ 
FTC, NNRTI 
LPV, SQV, ABC
YBF280 Dual M + O M + O K20I M36I V77I 
L89M
None L10V V11I I15V 
M36I I62V 
A71V K20C 
D60N/S L63I 
L89I
A98G K103R 
V179E L210Y
SQV ATV
YBF301 Dual M + O M + O L10V K20I 
L24L/I M36I 
L89M
None SQV L10V I15V M36I 
I62V A71V 
K20C L63T/A 
L89M
M184V A98G 
K103R V179E 
Y181C L210Y
SQV, 3TC/FTC, 
NNRTI ATV, 
ABC
YBF320 Dual M + O M + O K20I M36I 
L89M
K101Q L10I/V I15V 
M36I I62V 
A71V K20C 
L63T L89I
A98G V179E 
Y181C L210Y
SQV, NNRTI ATV
YBF211 Dual + recombi‑
nant
M + O M + O I15L K20I M36I 
L63P L89M
None L10V I15V M36I 
I62V A71V 
K20C L63T 
L89I
A98G V179E 
Y181C L210Y
SQV, NNRTI ATV
YBF212 Dual + recombi‑
nant
M + O M + O K20I M36I 
L89M
E138A V179I 
K101Q
RPV ETR L10I I15V L33V 
M36I I62V 
A71V/I K20C 
F53Y/C D60S 
L63A L89I
A98G V179E 
Y181C L210Y
ATV, SQV, NNRTI
YBF205 Dual + recombi‑
nant
M + O O K20I L24L/I 
M36I L89M
SQV L10I I15V 
M36I I62V 
A71V K20C 
D60N/S L63T 
L89I
A98G K103R 
V179E L210Y
SQV ATV
YBF274 Sin‑
gle + Recom‑
binant
O O – – L10V/I I15V 
M36I D60E 
I62V A71V 
K20C L63T 
L89I
A98G V179E 
Y181C L210Y
ATV, SQV, NNRTI
YBF298 Single + recom‑
binant
M M K20I D30N 
M36I D60N 
G73S L89M
None NFV SQV – – –
YBF282 Recombinant 
alone
M M G16E K20I 
M36I L63P/L 
L89M
None ‑ ‑
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on three hypotheses: (1) M + O dual infections are the 
pre-requisite for the genesis of HIV-1/MO recombinant 
forms (as the three recombinants described by 2004 were 
in patients with parental strains [10–12]; detecting dual 
infections may facilitate detection of recombinants), (2) 
vpr is a hotspot of recombination between HIV-1/M 
and HIV-1/O (two of the three MO recombinants forms 
exhibited a vpr breakpoint [10–12], and (3) since a break-
point was found two times in vpr and once in the Inte-
grase, the mosaic pattern could be as simple as pol O–env 
M or pol M–env O, so that performing molecular analy-
ses in these regions could be sufficient to detect putative 
recombinant forms.
The first step was to perform serotyping screen-
ing based on V3-O and V3-M antigens, to discriminate 
between HIV-1/M or HIV-1/O mono- and dual- sero-
reactivities easily and rapidly among the 21 796 samples 
available. We detected 142 samples with reactivity at least 
against the group O antigen, among which 53 (37.3%) 
presented with M  +  O dual reactivities. As previously 
described, this serotyping can present cross-reactivity 
[35], since 29/39 samples were concluded as mono-
infection by PCR (HIV-1/M: n =  6; HIV-1/O: n =  23). 
Therefore, dual seroreactivity must not be systematically 
concluded as dual infection. Despite these limitations, 
our results showed that our serotyping screening strat-
egy was useful for selecting samples with possible dual 
infections with or without recombinant forms for further 
additional molecular exploration.
The second step was to perform molecular inves-
tigation using group-specific PCRs. Among the 10 
samples with dual seroreactivities, we identified: (1) 4 
HIV-1/M + O dual infections without evidence of a vpr 
recombinant; (2) 5 vpr recombinants associated with 
one or both parental strains; and (3) 1 vpu recombinant 
without parental strains. All these cases are new except 
for YBF298, which could correspond to the 97CA.MP645 
strain previously described or to this strain transmitted 
to another patient with an epidemiological link.
The diversity patterns of the six recombinant forms 
were coherent with HIV molecular epidemiology in 
Cameroon, since they implied parental HIV-1/O sub-
group H (6/6) and HIV-1/M subtype CRF02_AG (4/6, 
67%), the most prevalent forms of each group [15, 36]. 
Thus, our work has shown that the co-circulation of 
HIV-1/M and HIV-1/O leads to dual infections and 
recombinant forms that could correspond to as many 
URFs_MO as described for HIV-1/M. These data, and 
our recent report of the transmission of an URF_MO in 
a couple, highlight the fact that recombinants are circu-
lating in Cameroon, are more numerous than initially 
thought, and that a CRFs_MO or _OM could emerge in 
the next years. This hypothesis could be supported by the 
previous report that an MO recombinant form is more 
replicative than the parental strains [10].
The impact on public health of these dual infections and 
recombinants is difficult to predict. Paradoxically, even 
though we found a relatively small number of dual sero-
reactivities (53 among the 21 796 samples), these atypical 
infections accounted for 26% of dual seroreactive sam-
ples, highlighting that these phenomena are not as rare 
as previously thought. The negative impact of the genetic 
diversity of group O on serological diagnosis, resistance to 
NNRTI-based treatments and RNA plasmatic misquan-
tification is now well-known. Similarly, the circulation of 
M  +  O dual infections and/or mosaic strains including 
group O fragments could have deleterious consequences. 
Thus, recombinant forms with a group O envelope (in 
absence of parental forms) will not be diagnosed by 
serological tests that are not adapted to this group due 
to antigenic variability [17, 18, 37], thus enabling silent 
spreading of these viruses. Moreover, if M  +  O dual 
infections and recombinants with group O fragments 
(particularly in RT) are unknown, unadapted therapeu-
tic management could lead to rapid virological failure 
of the cART due to the natural resistance of group O to 
NNRTIs, and subsequently to the emergence of strains 
resistant to other partner drugs. We have shown here 
that some HIV-1/M species and many HIV-1/O species 
are resistant or possibly resistant to many drugs; some of 
these mutations are classically found in HIV-1/M non-B 
subtypes or correspond to the natural polymorphism of 
HIV-1/O [22]. But, some others are selected under pres-
sure of cART, as M184V or D30N for example, indicat-
ing that even in absence of therapeutic data, patients may 
have had a cART. This natural polymorphism together 
with selected mutations as found in YBF221 and YBF301 
dual infections (Table  2) is of concern if a recombinant 
form emerges with the virological properties of HIV-1/M 
associated with the multi-resistance pattern of the HIV-
1/O species. Another concern is the virological follow-
up, which if performed with a group specific technique, 
may underestimate the viral populations according to the 
amplified regions; paradoxically, the development of non-
specific viral load kits (RealTime HIV-1, Abbott; Cobas 
TaqMan HIV-1 v.2, Roche for example) will quantify 
global M +  O populations without distinguishing them, 
and will lead to the non-identification of recombinants. 
As a consequence, knowledge of these particular cases of 
multiple and recombinant infections is essential for accu-
rate virological monitoring and therapeutic management 
with specific tools. We already observed an HIV-1 group 
M superinfection in an HIV-1 group O-infected patient in 
a pregnancy context [38].
At an individual level, these dual infections and recom-
binant forms also raise questions about their natural 
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evolution, especially concerning pathogenesis compared 
to HIV-1/M or HIV-1/O mono-infections.
Our data reveal that the molecular epidemiology of 
HIV in Cameroon is becoming more complex; this is not 
surprising due to the wide genetic diversity of viruses cir-
culating in this region, but the situation is maybe even 
more complex. Indeed, our work has several limitations 
that could underestimate the prevalence of M + O dual 
infections and recombinant forms. The sample collec-
tion, performed from 2006 to 2009 and not according to 
epidemiological methodology, may not be representative 
of the current situation and cannot define the prevalence 
or frequency of such forms. We only analyzed M  +  O 
dual seroreactivity, but reports of two cases with recom-
binants only [13, 14] and a third case here (YBF282) raise 
the question of the circulation of a single recombinant 
with a serotype profile of HIV-1/M or/O mono-infection.
We searched for vpr recombinants, because we consid-
ered this gene as a potential hot-spot of recombination; 
indeed, three of four MO recombinant forms previously 
reported exhibited a vpr breakpoint. This and our data 
show that this region could be essential for MO recom-
bination, compared to intra-group HIV-1/M recombi-
nation. Among the HIV-1/M CRFs, reported in the Los 
Alamos Database, only 12 show a recombinant breakpoint 
in vpr. The only HIV-2 circulating recombinant form 
has no breakpoint in the vpr gene. But, we also found a 
vpr recombinant, because we focused on this gene; the 
description of two recombinant forms with a breakpoint 
outside vpr, in vpu here (as well as at the end of env) and 
in Integrase in a previous report [12], highlights the fact 
that some recombinants do not harbor such a breakpoint, 
and that the situation could be more complex as for HIV-
1/M CRFs. Thus, we report here four cases of dual infec-
tion without vpr recombinant, even though they may have 
recombinant viruses with another breakpoint. There is a 
crucial need to sequence the whole genome of these par-
tial forms to identify other breakpoints. But full-length 
sequencing of multiple distinct populations present in the 
samples is technically difficult, even by cloning; we need 
to optimize such tools or use next generation sequenc-
ing technology, more adapted to discriminating between 
numerous populations. Lastly, we analyzed RNA or DNA 
forms according to the material available and at a unique 
sampling point for each patient, but dual infections and 
recombination are dynamic processes, combining co-
infection or superinfection, emergence and selection of 
recombinants, and potential disappearance of one or both 
parental strains. To better understand these dynamics and 
the emergence of more adapted forms, we need to analyze 
sequential samples, and both DNA and RNA to distin-
guish between archived and replicative forms.
In conclusion, our combined sero-molecular strat-
egy allowed us to identify new inter-group HIV-1/MO 
recombinant forms, with characterization of two com-
pletely new genomes, associated or not with dual infec-
tions. This work highlights the dynamic co-evolution of 
these two groups of strains in Cameroon; a new study 
taking into account our limitations is in process to better 
estimate the prevalence and genetic pattern of the [MO]/
[OM] recombinants.
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